MRC Technology joins project UTILE to enable medical breakthroughs from European funded research

MRC Technology is committed to ensuring that promising medical research is protected and progressed to benefit patients.…

MRC Technology appoints Steve Visscher as new trustee

MRC Technology has appointed Steve Visscher CBE to its board of trustees.

MRC Technology, Cancer Research UK and Cancer Research Technology collaborate to focus on cancer immunotherapies

Cancer Research UK, Cancer Research Technology and MRC Technology are joining forces to identify and validate novel drug discovery targets that could lead to new immunotherapy treatments.

MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

Edinburgh, Scotland, 17 January 2017: MRC Technology, an independent medical research charity, has announced the relocation of…

MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

MRC Technology has announced the relocation of its Centre for Diagnostics Development (CDD) to Nine, Edinburgh BioQuarter. The move forms part of the charity’s investment of over £7million over the next five years to further its work accelerating diagnostic research into the clinic.

MRC Technology, UCB and the University of Leicester combine research excellence and expertise to evolve drug discovery

New research consortium aims to identify opportunities for drug discovery through the innovative use of antibodies in structure-based drug discovery and design.

New collaboration to explore novel treatments for respiratory diseases

A charity-industry collaboration has launched an initiative to find new epigenetic drug treatments to improve the lives of millions of people affected by respiratory diseases every year.

MRC Technology monetises royalties on cancer drug Keytruda® (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital

MRC Technology has monetised a portion of its royalty interest in a leading cancer drug, pembrolizumab (marketed by Merck & Co., Inc. as Keytruda®) with a private equity fund managed by DRI Capital (DRI) for US $150M (£115.6M).

MRC Technology and Keio University to collaborate on drug discovery

MRC Technology and Keio University School will collaborate to identify promising antibody and small molecule research and translate them into early stage assets.